ClinicalTrials.gg
Active, not recruitingNCT07541339SEDATE-PFAUpdated Oct 28, 2026

Safety and Efficacy of Conscious Sedation Versus General Anesthesia in Pulsed-Field Ablation for Paroxysmal Atrial Fibrillation

An interventional study of conscious sedation and General Anesthesia (control group) in Atrial Fibrillation (Paroxysmal), sponsored by Beijing Anzhen Hospital. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Beijing Anzhen Hospital · Not applicable, Interventional, and Treatment

How we know

Updated Oct 28, 2026Now Active, not recruitingGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
224
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Atrial Fibrillation by Beijing Anzhen Hospital — 25 open to participants now, 26 under way, 1 of them phase 3. Atrial Fibrillation · Beijing Anzhen Hospital.

Planned enrollment
19th of 24
224 · median 410
Started
2026
with 10 others
No phase
21 of 36
15 open now
Primary completion
2026-12
later than 5 of 25 live
Registered
32nd of 36
by date

Among the 36 studies in Atrial Fibrillation by Beijing Anzhen Hospital, this one is the 19th largest by planned enrollment of the 24 interventional ones that give a count, is one of 11 that started in 2026, is one of 21 with no phase, reaches primary completion later than 5 of the 25 other live ones, and was the 32nd registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

25 of the 36 studies in Atrial Fibrillation by Beijing Anzhen Hospital are open now, in 1 country. Recruiting first, the newest first:

20 more — sign in →

By country, each count listing its studies:

All 25 open studies →

Where they have run

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Atrial Fibrillation by Beijing Anzhen Hospital, or all of them as a file.
02

Study summary

The goal of this clinical trial is to compare the safety and efficacy of conscious sedation and general anesthesia in patients with paroxysmal atrial fibrillation undergoing their first pulsed-field ablation (PFA) procedure. It will also establish a scalable conscious sedation protocol for PFA. The main questions it aims to answer are:

  1. Does conscious sedation reduce the incidence of the composite safety endpoint (persistent hypotension or hypoxemia for more than 60 seconds intraoperatively) compared with general anesthesia?
  2. What are the differences in perioperative indicators and adverse events between the two anesthetic strategies in PFA for paroxysmal atrial fibrillation? Researchers will randomly assign eligible patients to a conscious sedation group or a general anesthesia group at a 1:1 ratio to compare the safety and efficacy of the two anesthetic approaches.

Participants will:

  1. Receive the assigned anesthetic strategy combined with standardized PFA procedure
  2. Complete intraoperative vital sign and related index monitoring
  3. Undergo follow-up visits at 12-24 hours, 30 days and 90 days after surgery for relevant index assessment and adverse event recording
Read the detailed description

Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia, which severely impairs patients' quality of life and is closely associated with an elevated risk of complications including thromboembolism and heart failure. Rhythm control, particularly catheter ablation, has become a cornerstone of AF management. In recent years, pulsed-field ablation (PFA) has emerged as a novel catheter ablation technique for AF. It demonstrates non-inferior ablation efficacy to conventional radiofrequency ablation, with the advantages of minimal injury to peri-myocardial tissues, high procedural efficiency and a low incidence of complications, thus serving as a promising alternative for AF catheter ablation.

Unlike radiofrequency ablation, PFA delivers high-voltage electric fields during the procedure, for which local anesthesia fails to achieve satisfactory sedation and analgesia. General anesthesia (GA) is currently the main anesthetic approach for PFA to ensure adequate intraoperative immobilization and provide stable conditions for precise procedural manipulation. However, GA has notable limitations: first, the central inhibitory effects of general anesthetics and procedural stress-induced responses are prone to cause perioperative hemodynamic instability, leading to adverse events such as hypotension and hypoxemia, which not only increase procedural risks but also exert adverse impacts on short- and long-term patient prognosis; second, GA usually requires endotracheal intubation or laryngeal mask ventilation, which may cause retropharyngeal injury and raise the risk of complications like bleeding or hematoma; third, GA incurs relatively high medical costs, further increasing the economic burden on patients.

In light of these unmet clinical needs, several observational studies have demonstrated the feasibility of deep or conscious sedation during PFA procedures. Nevertheless, sedation strategies vary across centers, and most findings are based on single-center, small-sample empirical summaries, lacking high-quality evidence from large-sample, rigorously designed randomized controlled trials (RCTs). Our team has previously explored a conscious sedation strategy in over 200 patients, and the results showed that this strategy could achieve satisfactory sedation and analgesia for PFA, significantly reduce the risk of GA-related hemodynamic instability, and yield favorable postoperative feedback from patients.

Given the sufficient evidence supporting the efficacy and safety of PFA in the treatment of paroxysmal atrial fibrillation (PAF), this study intends to conduct a single-center, 1:1 randomized, single-blind controlled trial to compare the safety and efficacy of conscious sedation and GA in PFA for PAF, aiming to provide an evidence-based basis for the selection of an optimal sedation regimen for PFA procedures.

03

Conditions studied

  • Atrial Fibrillation (Paroxysmal)

Browse trials for

Keywords

  • Paroxysmal atrial fibrillation
  • Pulsed-field ablation
  • Conscious sedation
  • General anesthesia
  • Efficacy
  • Safety
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 to 80 years
  • Diagnosed with paroxysmal atrial fibrillation
  • No prior history of catheter ablation for atrial fibrillation/atrial flutter
  • Scheduled to undergo pulsed-field ablation
  • Provide written for study participation and be able to complete all scheduled follow-up assessments

Exclusion criteria

Exclusion Criteria:

  • Obstructive sleep apnea-hypopnea syndrome (OSAHS)
  • Complicated with severe (COPD), asthma or other respiratory system diseases
  • (BMI) >30 kg/m² or \<20 kg/m²
  • Preoperative pulse oxygen saturation (SpO₂) \<93%
  • Anticipated difficult airway
  • Intolerance to general anesthesia ( [ASA] physical status ≥Ⅳ)
  • Current (LVEF) ≤40% or (NYHA) functional class Ⅲ-Ⅳ
  • Acute coronary syndrome within 3 months
  • Within 3 months after percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG) or other cardiac/vascular surgeries
  • Moderate/severe stenosis or severe regurgitation of aortic or mitral valve
  • Acute cerebrovascular disease within 1 month
  • Severe hepatic insufficiency ( Class C)
  • Estimated (eGFR) \<45 mL/min/1.73m² or on dialysis
  • History of chronic heavy alcohol consumption
  • History of substance abuse
  • to any medications used in the study protocol
  • Pregnancy or lactation
  • Concurrent participation in other interventional clinical trials
  • Other conditions deemed unsuitable for study participation by the investigators
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
224 participants (estimated)

Study arms

  • Experimental
    conscious sedation group

    A conscious sedation regimen based on remimazolam combined with fentanyl, plus lidocaine for antitussive therapy, administered by electrophysiologists.

    Procedure: conscious sedation

  • Active comparator
    General anesthesia group

    The general anesthesia group adopted a standardized general anesthesia process of remimazolam + sufentanil + rocuronium for anesthesia induction, and remimazolam + remifentanil for anesthesia maintenance.

    Procedure: General Anesthesia (control group)

Interventions

  • Procedureconscious sedation

    Medications: Remimazolam toluenesulfonate injection (25 mg) + Fentanyl citrate injection (0.1 mg) + Lidocaine (100 mg). Administration method: Remimazolam: 2 vials mixed with 50 mL of 0.9% sodium chloride injection to prepare a solution with a concentration of 1 mg/mL. The target Bispectral Index (BIS) is 60-80, and the infusion rate of remimazolam is adjusted according to the BIS and patient responses. Fentanyl citrate: 5 vials mixed with 50 mL of 0.9% sodium chloride injection to prepare a solution with a concentration of 0.01 mg/mL. Dose reduction and slower injection rate are required for patients with hepatic/renal insufficiency, obesity, or elderly/weak conditions.

  • ProcedureGeneral Anesthesia (control group)

    After femoral vein puncture, anesthesia induction was performed with remimazolam (0.2-0.3 mg/kg), sufentanil (0.3-0.4 μg/kg) and rocuronium (0.6 mg/kg) following standard monitoring and preoxygenation. A laryngeal mask airway was inserted upon loss of consciousness and adequate muscle relaxation, with lung-protective mechanical ventilation applied at tidal volume 6-8 mL/kg, respiratory rate 10-14 breaths/min, I:E 1:2, FiO₂ 60% and fresh gas flow 2-3 L/min to maintain PaCO₂ at 35-45 cmH₂O. Anesthesia was maintained with continuous intravenous ciprofol (0.4-1 mg/kg/h) and remifentanil (0.1-0.2 μg/kg/min) to keep BIS 60-80 and MAP \>70 mmHg, with vasoactive agents as needed. Anesthetics were discontinued before surgery end; the laryngeal mask airway was removed after the patient regained consciousness with satisfactory spontaneous breathing, and antagonistic drugs were used if necessary.

    Also known as: general anesthesia

06

What researchers measure

Primary outcomes

  1. Primary outcome

    persistent systolic blood pressure \<85 mmHg for more than 60 seconds, or persistent hypoxemia (SpO₂ \<85%) for more than 60 seconds.

    Time frame: During procedure

Secondary outcomes

  1. Individual components of the primary composite endpoint

    persistent systolic blood pressure \<85 mmHg for more than 60 seconds, or persistent hypoxemia (SpO₂ \<85%) for more than 60 seconds.

    Time frame: During procedure

  2. The number of occurrences of each component of the primary outcome

    The number of occurrences of each component of the primary outcome: (1) Systolic blood pressure persistently below 85 mmHg for more than 60 sec; or (2) Persistent hypoxemia (SpO₂ \< 85%) for more than 60 seconds.

    Time frame: During procedure

  3. Sedation difficulty score

    1-10; 1 = easiest, 10 = most difficult

    Time frame: During procedure

  4. Total procedure time

    from femoral vein puncture to sheath removal

    Time frame: During procedure

  5. Left atrial dwell time

    The duration that the catheter stays in the left atrium

    Time frame: During procedure

  6. Total number of ablations

    The total number of ablation discharges

    Time frame: During procedure

  7. Total ablation duration

    The total ablation discharge time

    Time frame: During procedure

  8. Fluoroscopy time

    Fluoroscopy time

    Time frame: During procedure

  9. Radiation dose

    Radiation dose

    Time frame: During procedure

  10. Acute pulmonary vein isolation rate

    Acute pulmonary vein isolation rate

    Time frame: During procedure

  11. Arterial PaCO₂ immediately before discontinuation of sedation/anesthesia

    Arterial PaCO₂ immediately before discontinuation of sedation/anesthesia

    Time frame: During procedure

  12. Operative Sedation Assessment Scale

    Please ask the patient to recall how much pain they felt during the surgery?(0-10, the higher the score, the more severe the pain)

    Time frame: 12-24 hours postoperatively

  13. Atrial fibrillation recurrence at 30 days post-procedure

    Atrial fibrillation recurrence at 30 days post-procedure

    Time frame: Day30

  14. Atrial fibrillation recurrence at 90 days post-procedure

    Atrial fibrillation recurrence at 90 days post-procedure

    Time frame: Day90

  15. Atrial fibrillation burden at 90 days post-procedure

    Use 3 days of electrocardiogram patch monitoring to assess the burden of atrial fibrillation(Atrial fibrillation burden (%) = Total duration of atrial fibrillation ÷ Effective monitoring duration × 100%)

    Time frame: Day90

  16. Serious adverse events

    SAE refers to adverse reactions that meet any of the following criteria: * Death or life-threatening * Resulting in severe and permanent disability * Requiring hospitalization or prolonging hospital stay * Causing congenital abnormalities or birth defects in offspring * A significant medical event determined by the researcher to cause major harm or injury to the subject, which may require drug treatment or surgical intervention to prevent the occurrence of other conditions as defined by SAE (such as death, permanent disability, hospitalization, etc.).

    Time frame: Day0-90

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Dec 2026, 8 months after the start.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 8 months is below that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2026
First posted
Apr 21, 2026
StartActual
Apr 1, 2026
Primary completionEst.
Dec 1, 2026
CompletionEst.
Mar 1, 2027
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Active, not recruiting
changed Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Not yet recruiting→Active, not recruiting
    + 2 other changes: date precision and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07541339
Responsible party
NingZhou (Professor, Beijing Anzhen Hospital) — Principal investigator
First posted
Apr 21, 2026
Start date
Apr 1, 2026
Primary completion
Dec 1, 2026 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
Oct 28, 2026

Study contacts

Ning Zhou
study chair · Beijing Anzhen Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion